AbbVie Acquired Mavupharma to Get Hold of Its STING Fever Drug

AbbVie recently completed the acquisition of a three-year-old Seattle-based startup Mavupharma. The acquisition gives the company access to the startup’s STING fever program. The company has become the latest in the line of pharma and biotech companies developing cures for the emerging immune-oncology target. What does Mavupharma acquisition mean? The STING fever drug helps in…